MK-8776, a novel chk1 kinase inhibitor, radiosensitizes p53-defective human tumor cells

Radiotherapy is commonly used to treat a variety of solid tumors but improvements in the therapeutic ratio are sorely needed. The aim of this study was to assess the Chk1 kinase inhibitor, MK-8776, for its ability to radiosensitize human tumor cells. Cells derived from NSCLC and HNSCC cancers were t...

Descripción completa

Detalles Bibliográficos
Autores principales: Bridges, Kathleen A., Chen, Xingxing, Liu, Huifeng, Rock, Crosby, Buchholz, Thomas A., Shumway, Stuart D., Skinner, Heath D., Meyn, Raymond E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342109/
https://www.ncbi.nlm.nih.gov/pubmed/27690219
http://dx.doi.org/10.18632/oncotarget.12311

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342109/
https://www.ncbi.nlm.nih.gov/pubmed/27690219
http://dx.doi.org/10.18632/oncotarget.12311

Ejemplares similares